3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Brain Neoplasms
3
Urinary Bladder Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Osteosarcoma
1
Osteonecrosis
1
Osteomyelitis
1
Lung Carcinoma Metastatic in the Brain
1
Kidney Neoplasms
1
Glioblastoma
1
Cranial Nerve Diseases
1
Chondrosarcoma
1
Central Nervous System Neoplasms
1
Bone Neoplasms
1
Interventions
Cyclophosphamide
11
Vincristine
9
Temozolomide
7
Magnetic Resonance Spectroscopy
6
Irinotecan
6
Filgrastim
6
Etoposide
6
Doxorubicin
6
X-Rays
5
Phantoms, Imaging
5
Ifosfamide
5
Dactinomycin
5
cixutumumab
4
Vinorelbine
4
Specimen Handling
4
Sirolimus
4
Nuclear Medicine Department, Hospital
4
Melphalan
4
Gemcitabine
4
pegfilgrastim
3
palbociclib
3
Tacrolimus
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Dexrazoxane
3
Biopsy
3
ulixertinib
2
tipifarnib
2
thymoglobulin
2
temsirolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Rhabdomyosarcoma
×
Ferrosoferric Oxide
×
Clear all
NCT01336803
2023-12-27
Osteosarcoma
Stanford University
Phase 2
Completed
32 enrolled
11 charts